STAT

Opinion: Advancing AI in health care: It’s all about trust

In drug trials, success in Phase 1 is no guarantee of success in Phase 3. In the current mania for AI and deep learning, a proof of concept is taken…

Three years ago, artificial intelligence pioneer Geoffrey Hinton said, “We should stop training radiologists now. It’s just completely obvious that within five years, deep learning is going to do better than radiologists.”

Today, hundreds of startup companies around the world are trying to apply deep learning to radiology. Yet the number of radiologists who have been replaced by AI is approximately zero. (In fact, there is a worldwide shortage of them.)

At least for the short term, that number is likely to remain unchanged. Radiology has proven harder to automate than Hinton — and many others — imagined. For medicine in general, this is no less true. There are many proofs of concept, such as from chest X-rays, but.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks